Metabolic dysfunction-associated steatotic liver disease
Last updated 1 Apr 2026
Meets Patient’s editorial guidelines
- DownloadDownload
- Share
- Language
- Discussion
- Ask Patient
- Audio Version
- Add to preferred sources on Google
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a condition that is characterised by a buildup of fat in the liver, which can lead to liver damage. The liver is part of the digestive system, and it helps break down food, store energy, and remove waste products. If more than 5 percent of the liver contains fat, the liver is considered to be fatty (steatotic).
Video picks for Genetic conditionsVideo library
Description
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a condition that is characterised by a buildup of fat in the liver, which can lead to liver damage. The liver is part of the digestive system, and it helps break down food, store energy, and remove waste products. If more than 5 percent of the liver contains fat, the liver is considered to be fatty (steatotic).
MASLD is most common among middle-aged or older people, although younger people, including children, may also be affected. People with MASLD have liver steatosis along with at least one of the following features: higher body weight, type 2 diabetes, or one of several metabolic abnormalities. The abnormalities that are included in the diagnosis of MASLD are pre-diabetes (insulin resistance), high levels of fats (lipids) such as cholesterol and triglycerides in the blood, or high blood pressure (hypertension). MASLD is estimated to occur in up to 75 percent of adults with obesity or high levels of lipids in the blood and in up to 65 percent of adults with type 2 diabetes.
In people with MASLD, the fat deposits in the liver can cause increased levels of liver enzymes that can be detected during routine blood tests. Some affected individuals have abdominal pain or fatigue. During a physical examination, the liver may be found to be slightly enlarged. In people with MASLD, the liver problems are not caused by alcohol use disorder.
MASLD is slow to worsen, or it may not worsen at all. In many affected individuals, the buildup of fat in the liver can be reduced by adopting healthy habits. However, up to 30 percent of people with MASLD develop inflammation of the liver (metabolic dysfunction-associated steatohepatitis, also known as MASH), which can damage the liver. In people with long-term liver damage, normal liver tissue may be replaced with scar tissue (fibrosis), resulting in permanent liver disease (cirrhosis) and, eventually, liver failure. People with MASLD, MASH, and cirrhosis have a higher risk of developing liver cancer (hepatocellular cancer). People with MASLD are also at increased risk of developing additional health problems such as heart (cardiovascular) disease.
Inheritance patterns
The source lists the following possible inheritance patterns: Pattern unknown. More than one pattern can apply in different cases.
Related genes
Other names
MASLD
NAFLD
Non-alcoholic fatty liver disease
Non-alcoholic steatohepatitis
Patient picks for Genetic conditions

Hormones
Insulin resistance: the common thread linking metabolic conditions
You may have come across the term “insulin resistance” - particularly if you’ve been having conversations about weight and metabolic health - but be a little unclear about what it actually is. Whilst it’s easy to think insulin resistance just means reduced glucose control, it’s actually far more complex than that. Dr Nienke Lees, Women's Health Service Lead, Genwell UK, explains what it means and how it connects conditions including type 2 diabetes, fatty liver disease, cardiovascular disease, and PCOS.
by Dr Nienke Lees

Cancer
Liver cancer deaths are rising - what you need to know
Liver cancer deaths have risen by more than a quarter over the past decade. That’s why we’re helping raise awareness of liver cancer alongside Liver UK. We want more people to recognise the symptoms and understand the risk factors, so they can take action early.
by Claire Kenny

Surgery and procedures
Liver biopsy
A liver biopsy involves taking a small sample of tissue from the liver. Liver cells can then be looked at in detail. It is used to diagnose and monitor certain conditions. Note: the information below is a general guide only. The arrangements, and the way tests are performed, may vary between different hospitals.It is vital to always follow the instructions given by the hospital at which the procedure is being performed.
by Dr Philippa Vincent, MRCGP

Digestive health
Liver failure
Liver failure occurs when large parts of the liver become damaged and can't be repaired. The liver is unable to work properly. Liver failure can make you feel very unwell. Acute liver failure is life-threatening and needs emergency medical care. Liver failure often develops slowly over many years. This is called chronic liver disease. See the separate leaflet called Cirrhosis for further information. Liver failure can also develop rapidly over just a few days (acute liver failure). There are many causes of acute liver failure. These include paracetamol poisoning, infections (for example, hepatitis B or hepatitis C), acute fatty liver of pregnancy and a number of rare genetic conditions. For some people with liver failure the cause is not known.
by Dr Hayley Willacy, FRCGP

Healthy living
How modern life affects your weight - beyond diet and exercise
If our bodies are designed to regulate our weight, why are more people living with obesity than ever before? Our genes haven't changed significantly over recent decades, but our environment, lifestyles, and individual biology all influence how our bodies regulate hunger, burn energy, and store fat. Understanding these factors can help explain why managing weight is more difficult for some people than others, even when they're trying to make healthier choices.
by Dr Caroline Butler

Digestive health
Non-alcoholic fatty liver disease
Non-alcoholic fatty liver disease (NAFLD) describes a range of conditions caused by a build-up of fat within liver cells.
by Dr Doug McKechnie, MRCGP
Related patient information and medicines

Patient information leaflet
Liver biopsy
Note : the information below is a general guide only. The arrangements, and the way tests are performed, may vary between different hospitals.It is vital to always follow the instructio... Why is a liver biopsy done. A liver biopsy is done to diagnose and monitor damage or disease of the liver. This can include cirrhosis Cirrhosis , some metabolic.

Patient information leaflet
Liver failure
Liver failure occurs when large parts of the liver become damaged and can't be repaired. Diseases of the veins in the liver Some diseases (for example, Budd-Chiari syndrome) can cause blockages in the veins of the liver, w... Metabolic diseases Some rare metabolic diseases may cause acute liver failure. These include haemochromatosis.

Patient information leaflet
Non-alcoholic fatty liver disease
Non-alcoholic fatty liver disease (NAFLD) describes a range of conditions caused by a build-up of fat within liver cells. Most people with NAFLD do not develop serious liver problems. Only a minority will progress to develop inflammation of the liver (called non-alcoholic steatohepatitis, or NASH). Non-alcoholic steatohepatitis (NASH) n this.

Patient information leaflet
Gilbert's syndrome
Gilbert's syndrome is due to an inherited defect in processing bilirubin in the liver. What is Gilbert's syndrome. Gilbert's syndrome - also known as constitutional hepatic dysfunction - is a condition where the liver does not process bilirubin very well. It is sometimes called Gilbert's disease although it does not cause 'disease' as such. It is.

Patient information leaflet
Primary biliary cholangitis
Primary biliary cholangitis (PBC) is a condition that slowly damages the bile ducts in your liver, leading to liver damage and, sometimes, liver scarring (cirrhosis). Primary biliary cholangitis (PBC) is an auto-immune condition in which your immune system gradually destroys the tiny tubes (bile ducts) which take bile from the liver to the gut.

Patient information leaflet
Liver function tests
Liver function tests are a set of blood tests commonly done to check on the health of your liver. Changes in liver function tests give a clue as to whether your liver is under strain, inflamed, infected or diseased, and how badly. The pattern of the liver function tests can give a clue to the cause and can allow early detection of unsuspected.
Further reading and references
- Metabolic dysfunction-associated steatotic liver disease; MedlinePlus, National Library of Medicine.
- Ajmera V, Cepin S, Tesfai K, Hofflich H, Cadman K, Lopez S, Madamba E, Bettencourt R, Richards L, Behling C, Sirlin CB, Loomba R. A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes. J Hepatol. 2023 Mar;78(3):471-478. doi: 10.1016/j.jhep.2022.11.010. Epub 2022 Nov 19.
- Eslam M, Sanyal AJ, George J; International Consensus Panel. MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology. 2020 May;158(7):1999-2014.e1. doi: 10.1053/j.gastro.2019.11.312. Epub 2020 Feb 8.
- Huang DQ, Wong VWS, Rinella ME, Boursier J, Lazarus JV, Yki-Jarvinen H, Loomba R. Metabolic dysfunction-associated steatotic liver disease in adults. Nat Rev Dis Primers. 2025 Mar 6;11(1):14. doi: 10.1038/s41572-025-00599-1.
- Kahali B, Halligan B, Speliotes EK. Insights from Genome-Wide Association Analyses of Nonalcoholic Fatty Liver Disease. Semin Liver Dis. 2015 Nov;35(4):375-91. doi: 10.1055/s-0035-1567870. Epub 2015 Dec 16.
- Krawczyk M, Portincasa P, Lammert F. PNPLA3-associated steatohepatitis: toward a gene-based classification of fatty liver disease. Semin Liver Dis. 2013 Nov;33(4):369-79. doi: 10.1055/s-0033-1358525. Epub 2013 Nov 12.
- Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, Romero D, Abdelmalek MF, Anstee QM, Arab JP, Arrese M, Bataller R, Beuers U, Boursier J, Bugianesi E, Byrne CD, Narro GEC, Chowdhury A, Cortez-Pinto H, Cryer DR, Cusi K, El-Kassas M, Klein S, Eskridge W, Fan J, Gawrieh S, Guy CD, Harrison SA, Kim SU, Koot BG, Korenjak M, Kowdley KV, Lacaille F, Loomba R, Mitchell-Thain R, Morgan TR, Powell EE, Roden M, Romero-Gomez M, Silva M, Singh SP, Sookoian SC, Spearman CW, Tiniakos D, Valenti L, Vos MB, Wong VW, Xanthakos S, Yilmaz Y, Younossi Z, Hobbs A, Villota-Rivas M, Newsome PN; NAFLD Nomenclature consensus group. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Ann Hepatol. 2024 Jan-Feb;29(1):101133. doi: 10.1016/j.aohep.2023.101133. Epub 2023 Jun 24.
- Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D, Kleiner DE, Loomba R. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023 May 1;77(5):1797-1835. doi: 10.1097/HEP.0000000000000323. Epub 2023 Mar 17. No abstract available.
- Seko Y, Yamaguchi K, Shima T, Iwaki M, Takahashi H, Kawanaka M, Tanaka S, Mitsumoto Y, Yoneda M, Nakajima A, Okanoue T, Itoh Y. Clinical Utility of Genetic Variants in PNPLA3 and TM6SF2 to Predict Liver-Related Events in Metabolic Dysfunction-Associated Steatotic Liver Disease. Liver Int. 2025 Apr;45(4):e16124. doi: 10.1111/liv.16124. Epub 2024 Oct 7.
- Severson TJ, Besur S, Bonkovsky HL. Genetic factors that affect nonalcoholic fatty liver disease: A systematic clinical review. World J Gastroenterol. 2016 Aug 7;22(29):6742-56. doi: 10.3748/wjg.v22.i29.6742.
- Yu J, Marsh S, Hu J, Feng W, Wu C. The Pathogenesis of Nonalcoholic Fatty Liver Disease: Interplay between Diet, Gut Microbiota, and Genetic Background. Gastroenterol Res Pract. 2016;2016:2862173. doi: 10.1155/2016/2862173. Epub 2016 May 9.
Share your thoughts or experiences with others in our patient communities.
Sign up to the Patient newsletter
Your weekly dose of clear, trustworthy health advice - written to help you feel informed, confident and in control.
By subscribing you accept our Privacy Policy. You can unsubscribe at any time. We never sell your data.

